Sector News

Achaogen seeks near-term sale through bankruptcy process

April 16, 2019
Life sciences

Achaogen is looking to sell its assets and close out its affairs through the bankruptcy process. News of the Chapter 11 filing comes 10 months after Achaogen won FDA approval for its antibiotic Zemdri.

The run-up to the FDA approval of Zemdri proved to be the high watermark for Achaogen. While the FDA cleared Zemdri for use in complicated urinary tract infections, it rejected the drug in the treatment of bloodstream infections. That sent Achaogen into a downward spiral that led the company to lay off staff and seek a buyer for the business.

Now, five months after starting to search for a buyer, Achaogen has identified Chapter 11 bankruptcy as its best hope of getting some money for its assets.

“The Achaogen board of directors and management team have thoroughly assessed our strategic options and financial situation and unanimously agree that this structured sale process represents the best possible solution for the company,” Achaogen CEO Blake Wise said in a statement.

Notably, the process will allow buyers to acquire assets from Achaogen without taking on its debt and liabilities. Achaogen turned to debt to keep the business going when its plummeting stock price made raising money through share offerings less attractive.

Management at Achaogen thinks the $25 million in credit provided by Silicon Valley Bank will fund it through the Chapter 11 process. The first big milestone in the process comes when the window for submitting bids closes toward the end of May. A structured auction is due to start days later with a view to conclude the sale by mid-June.

The level of interest in Achaogen’s assets will depend on whether people think Zemdri can live up to the upbeat outlook that saw the biotech’s stock trade above $20 in 2017. Achaogen failed to deliver on expectations for the drug, but other products previously rescued from bankruptcy, such as Dendreon’s Provenge, have gone on to make significant sales.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach